Our Neuroscience Goals
We focus on modulating neuroinflammation, facilitating neuroprotection, repair, and remyelination in neurological diseases, and slowing down or halting neurodegeneration.
A Shared Commitment
We partner with companies that share our commitment and bring expertise in translational neuroscience and technologies.
Partnering Success Stories
Denali Therapeutics
We’re collaborating to develop RIPK1 inhibitors for potential treatments of neurological and inflammatory diseases, such as Alzheimer’s, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis.
ABL Bio
We’re collaborating to develop a potential first-in-class, bi-specific alpha-synuclein antibody for Parkinson’s disease. It’s designed as a “brain shuttle” that targets insulin-like growth factor 1 receptors.
Your Partnering Leads in Neuroscience
For more information, contact our Business development team
Brian Bronk
Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms
Guy Griebel
Head of External Innovation, Rare and Neurological Disorders